Vantrexa · SCLC · France · Pathologist · captured by Rachel Adeyemi on 19 Mar 2026 · reviewed by Dr. Sophie Laurent on 21 Mar 2026
Verbatim as captured; never edited
Pathologist at Institut Curie raised pd-l1 testing turnaround during a congress meeting. They indicated this influences their current prescribing approach.
Human-approved by Dr. Sophie Laurent on 21 Mar 2026
PD-L1 testing turnaround: request for data reported by pathologist (FR).
helixor-private-llm-2026.05 · generated 19 Mar 2026, 10:00 UTC
AI summary
PD-L1 testing turnaround raised by pathologist; suggest routing to Clinical Development.
Source spans used by the model
Pathologist at Institut Curie raised pd-l1 testing turnaround during a congress meeting. They indicated this influences their current prescribing approach.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Efficacy | Efficacy |
| Function | Clinical Development | Clinical Development |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 1 | 20% | 4.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 2 | 15% | 6.0 |
| Urgency | 4 | 15% | 12.0 |
| Novelty | 2 | 10% | 4.0 |
| Actionability | 3 | 10% | 6.0 |
| Confidence | 2 | 5% | 2.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | Medium 55 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
No further actions; record is archived.
Who reviewed, what action, which function, what decision, what outcome, when closed
17 Mar 2026 · Dr. Gabriel Ueda, Institut Curie · MSL Rachel Adeyemi
Insight
Reviewed 21 Mar 2026 by Dr. Sophie Laurent
Action
Initiative
Decision
Outcome
Closure
Shared with Clinical Development; no further action required.